A comprehensive evaluation of Naftifine's efficacy and safety in treating dermatophyte infections; systematic review and meta-analysis.

Dermatophyte infections, including tinea pedis (athlete's foot), tinea corporis (ringworm), and tinea cruris (jock itch), are widespread fungal infections that significantly impact global health and quality of life. Naftifine, an allylamine antifungal agent, is noted for its potent fungicidal activity, targeting fungal cell membranes by inhibiting squalene epoxidase. Additionally, Naftifine has anti-inflammatory and antibacterial properties, enhancing its therapeutic potential. This systematic review and meta-analysis aims to comprehensively evaluate the efficacy and safety of Naftifine in treating tinea pedis, tinea corporis, and tinea cruris, focusing on clinical outcomes, cure rates, and adverse effects to provide a thorough understanding of its effectiveness in managing these infections. This meta-analysis followed the PRISMA guidelines and included randomized controlled trials (RCTs) assessing naftifine's efficacy and safety in treating tinea pedis, corporis, and cruris. A systematic search was conducted in major databases from inception until February 9th, 2024. Eligible studies were selected based on predefined inclusion criteria, and data were extracted and analyzed using RevMan software. Seven multicenter RCTs were included in the meta-analysis. Naftifine demonstrated superior efficacy compared to vehicle control in terms of complete cure rate (RR = 5.83, 95% CI [3.73 to 9.10]) with no significant heterogeneity (I2 = 0%), clinical improvement [RR = 1.55, 95% CI (1.21-2.00)], and treatment effectiveness [RR = 3.93, 95% CI (2.44-6.33)] for tinea pedis. Similarly, for tinea corporis and cruris, Naftifine demonstrated significant efficacy compared to vehicle control regarding complete cure rate, mycological cure rate, clinical improvement, and treatment effectiveness. However, there was no significant difference in adverse events between Naftifine and the vehicle across all three conditions. Naftifine is an effective topical treatment for tinea pedis, corporis, and cruris, with a favorable safety profile with no significant difference in adverse events compared to the vehicle.